A Prospective, Non-interventional, Single Arm Study Investigating Long-term Glycaemic Control in Patients With Type 2 Diabetes Initiating Xultophy® (IDegLira) in a Realworld Setting in Italy
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Insulin degludec/liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REX
- Sponsors Novo Nordisk
- 18 Jan 2023 Status changed from active, no longer recruiting to completed.
- 19 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 18 Jun 2022 Trial design and results of the interim analysis performed to describe baseline clinical characteristics of patients at the time of IDegLira treatment initiation and the reasons for the choice of IDegLira treatment published in the Diabetes Therapy.